GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surface Oncology Inc (NAS:SURF) » Definitions » Net Interest Income

Surface Oncology (Surface Oncology) Net Interest Income : $-5.77 Mil (TTM As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Surface Oncology Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Surface Oncology's net interest income for the three months ended in Jun. 2023 was $-3.11 Mil. Its net interest income for the trailing twelve months (TTM) ended in Jun. 2023 was $-5.77 Mil.


Surface Oncology Net Interest Income Historical Data

The historical data trend for Surface Oncology's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surface Oncology Net Interest Income Chart

Surface Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Interest Income
Get a 7-Day Free Trial 2.55 -0.15 -2.86 -2.55 -3.15

Surface Oncology Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.73 -0.83 -0.90 -0.93 -3.11

Surface Oncology Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Surface Oncology Net Interest Income Related Terms

Thank you for viewing the detailed overview of Surface Oncology's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Surface Oncology (Surface Oncology) Business Description

Traded in Other Exchanges
N/A
Address
50 Hampshire Street, 8th Floor, Cambridge, MA, USA, 02139
Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors in the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Geographically, the activities are carried out throughout the region of the United States.
Executives
Chandra Adams officer: Deputy GC SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Alison Oneill officer: Chief Medical Officer
Jessica Fees officer: See Remarks C/O SURFACE ONCOLOGY, ICN., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139
Robert W. Ross officer: Chief Medical Officer C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Henry C. Rath officer: Chief Business Officer C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FL, CAMBRIDGE MA 02139
Vito J. Palombella officer: Chief Scientific Officer 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Carsten Brunn director C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Theresa Boni officer: General Counsel C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Benjamin Hickey director C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121
Liisa I Nogelo officer: General Counsel C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139
Jeff Goater director, officer: Chief Executive Officer C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
David S. Grayzel director C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Ix, L.p. 10 percent owner 46 WAREHAM STREET, FLOOR 3, BOSTON MA 02118
Atlas Venture Associates Ix, Llc 10 percent owner 56 WAREHAM STREET, FLOOR 3, BOSTON MA 02118

Surface Oncology (Surface Oncology) Headlines

From GuruFocus

Surface Oncology to Participate in Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 07-06-2022

Surface Oncology Appoints Carsten Brunn to Board of Directors

By GuruFocusNews GuruFocusNews 07-09-2022